{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-002261","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2022-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.107185+00:00","generated_at":"2026-06-25T05:27:26.886912+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Chemomab Director Joel Maryles to step down at 2022 AGM","bullets":["Joel Maryles, Class I director, notified Chemomab on May 31, 2022 he will not seek re-election.","Departure effective at the 2022 Annual General Meeting on June 7, 2022.","Departure not due to any disagreement with the Company, management, board, or operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-002261","json":"https://secwatch.observer/filing/0001178913-22-002261.json","markdown":"https://secwatch.observer/filing/0001178913-22-002261.md","text":"https://secwatch.observer/filing/0001178913-22-002261.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322002261/0001178913-22-002261-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322002261/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:27:26.886912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85f14ea68c","claim":"Joel Maryles departed as Class I Director at Chemomab Therapeutics Ltd..","evidence_excerpt":"On May 31, 2022, Joel Maryles, a member of the Board of Directors (the “Board”) of Chemomab Therapeutics Ltd. (the “Company”), notified the Company that he will not stand for re-election at the Company’s 2022 Annual General Meeting of shareholders, to be held on June 7, 2022, and, accordingly, Mr. Maryles’ term as a Class I director will expire at the 2022 Annual General Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322002261/0001178913-22-002261-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not standing for re-election"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}